Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 121 to 135 of 392 results for objectives

  1. MiraQ for assessing graft flow during coronary artery bypass graft surgery (HTG275)

    Evidence-based recommendations on MiraQ for assessing graft flow during coronary artery bypass graft surgery.

    HealthTech guidance
    Last updated
    5 July 2022
    View recommendations

    Sections for HTG275

  2. Sotorasib for previously treated KRAS G12C mutation-positive advanced non-small-cell lung cancer (TA781)

    Evidence-based recommendations on sotorasib (Lumykras) for previously treated KRAS G12C mutation-positive locally advanced or metastatic non-small-cell lung cancer in adults.

    Technology appraisal guidance
    Published
    30 March 2022
    View recommendations

    Sections for TA781

  3. Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after crizotinib (TA571)

    Evidence-based recommendations on brigatinib (Alunbrig) for treating anaplastic lymphoma kinase (ALK)-positive advanced non-small-cell lung cancer in adults who have already had crizotinib.

    Technology appraisal guidance
    Published
    20 March 2019
    View recommendations

    Sections for TA571

  4. Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy (TA378)

    Evidence-based recommendations on ramucirumab (Cyramza) for treating advanced gastric cancer or gastro-oesophageal junction adenocarcinoma previously treated with chemotherapy.

    Technology appraisal guidance
    Published
    27 January 2016
    View recommendations

    Sections for TA378

  5. Secukinumab for treating active non-radiographic axial spondyloarthritis (TA719)

    Evidence-based recommendations on secukinumab (Cosentyx) for treating active non-radiographic axial spondyloarthritis in adults.

    Technology appraisal guidance
    Published
    21 July 2021
    View recommendations

    Sections for TA719

  6. Antimicrobial stewardship: systems and processes for effective antimicrobial medicine use (NG15)

    This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.

    NICE guideline
    Published
    18 August 2015
    View recommendations

    Sections for NG15

  7. Pemetrexed for the maintenance treatment of non-small-cell lung cancer (TA190)

    Evidence-based recommendations on pemetrexed disodium (Alimta) for the maintenance treatment of non-small-cell lung cancer.

    Technology appraisal guidance
    Last updated
    10 August 2017
    View recommendations

    Sections for TA190

  8. TNF-alpha inhibitors for treating active ankylosing spondylitis and non-radiographic axial spondyloarthritis (TA383)

    Evidence-based recommendations on adalimumab (Humira), certolizumab pegol (Cimzia), etanercept (Enbrel), golimumab (Simponi) and infliximab (Remicade, Remsima, Inflectra). These drugs are for people with active ankylosing spondylitis or non-radiographic axial spondyloarthritis .

    Technology appraisal guidance
    Published
    1 February 2016
    View recommendations

    Sections for TA383

  9. icobrain ms for active relapsing–remitting multiple sclerosis (MIB291)

    NICE has developed a medtech innovation briefing (MIB) on icobrain ms for active relapsing–remitting multiple sclerosis .

    Medtech innovation briefing
    Published
    29 March 2022

  10. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA864

  11. How effective and cost effective are different types of intervention to prevent a range of cold-related illnesses and death? How do these vary with groups in different circumstances?

    applicable) They should be of a sufficient scale to be meaningful, use objective measurements and include 'natural experiments',...

    Research recommendation
    Published
    9 June 2015

  12. How can the design and reporting of the outcomes used in intervention studies be improved, so researchers can identify 'active ingredients'? Which validated tools are effective at consistently measuring success, especially in relation to health and wellbeing, performance, productivity and in economic terms?

    notes(if applicable) Research studies should collect both subjective and objective measureable outcomes of wellbeing. This will help...

    Research recommendation
    Published
    5 October 2015

  13. What are the symptoms of GORD in infants, children and young people with a neurodisability?

    differentiate from other vomiting problems. The proposed study would use objective measures of reflux (such as oesophageal pH...

    Research recommendation
    Published
    15 November 2019

  14. Paediatric early warning score (PEWS) as predictors of deterioration In children with bronchiolitis can paediatric early warning score (PEWS) predict deterioration?

    There are a number of clinical scores for bronchiolitis that include objective and subjective measures. No bronchiolitis score is...

    Research recommendation
    Published
    6 October 2015

  15. What are the symptoms of gastro-oesophageal reflux gastro-oesophageal reflux disease (GORD) in infants, children and young people with a neurodisability?

    differentiate from other vomiting problems. The proposed study would use objective measures of reflux (such as oesophageal pH...

    Research recommendation
    Published
    9 June 2015